ARKG Leads in 1-Week Returns as Biotech Rebounds

Biotech funds began their rebound last week as positive trial data and merger and acquisition news revived the sector. The ARK Genomic Revolution ETF (ARKG) rallied 7.15% over one week, ahead of all other ETFs in the health and biotech equities ETFs category, according to VettaFi. The actively...